Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

UNM professors create education pipeline to help students excel in STEM careers

For Angela Wandinger-Ness, PhD, giving back to society and investing in the future are the same thing. "That was the hook," she says. "If you're going to be in academics, you're there to do research and teaching and education."

2 Feb 2015

Scientists discover hidden mechanism which could explain why some cancer therapies fail trials

Scientists based at the University of Helsinki, Finland, have discovered a 'hidden' mechanism which could explain why some cancer therapies which aim to block tumour blood vessel growth are failing cancer trials.

31 Jan 2015

MD Anderson and AstraZeneca to conduct multiple studies in ovarian, gynecologic cancers

The University of Texas MD Anderson Cancer Center and AstraZeneca today announced a multiyear strategic research collaboration to conduct multiple, parallel clinical and clinically related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.

31 Jan 2015

UNC researchers discover how two genes interact to trigger worst form of ovarian cancer

In the battle against ovarian cancer, UNC School of Medicine researchers have created the first mouse model of the worst form of the disease and found a potential route to better treatments and much-needed diagnostic screens.

27 Jan 2015

BRCA1/2 analysis: an interview with Jurgi Camblong, CEO of Sophia Genetics

BRCA1 and BRCA2 genes are two of the most well studied genes in the cancer field. They are tumor suppressors - mutations in these genes can lead to breast and/or ovarian cancer. Predispositions can be detected in women before they develop cancer.

26 Jan 2015

NCCS launches human clinical trial of new cancer vaccine

The National Cancer Centre Singapore has launched a clinical trial of a new cancer vaccine administered to human patients for the first time in the world. Cancer immunotherapy (the harnessing of the body's defence system to fight the patient's cancer, has emerged as one of the most exciting medical breakthroughs in the past two years.

22 Jan 2015

VolitionRx initiates pilot study to assess effectiveness of NuQ assays for ovarian cancer

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced it has signed an agreement to commence a pilot ovarian cancer study in collaboration with Singapore General Hospital.

21 Jan 2015

Pfizer, Avon Foundation for Women reveal Avon-Pfizer Metastatic Breast Cancer Grants Program recipients

Today, Pfizer Inc. and the Avon Foundation for Women are proud to announce the first-ever recipients of the Avon-Pfizer Metastatic Breast Cancer Grants Program: Identify-Amplify-Unify.

21 Jan 2015

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Zeltia announces today that its pharmaceutical division PharmaMar will start a Phase III trial with PM1183 in combination with doxorubicin against topotecan in SCLC, given the activity observed in an interim analysis of an ongoing Phase Ib trial. The results of this study will be presented at a prominent international cancer meeting this year, which will be soon announced.

14 Jan 2015

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Sophia Genetics, the European leader in Data Driven Medicine, has today obtained CE-IVD marking for its solution to detect BRCA1/2 associated genetic variants in live tumours.

14 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research.

31 Dec 2014

Vermillion closes previously announced private placement with investors

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, announced today that the Company closed its previously announced private placement with investors including Oracle Investment Management, Jack W. Schuler, Birchview Fund LLC and several Vermillion directors. Total proceeds were $10.5 million, before offering expenses.

25 Dec 2014

Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

Oncolytics Biotech Inc. ("Oncolytics") today announced that it has submitted applications for Orphan Designation to the European Medicines Agency ("EMA") for REOLYSIN® for the treatment of pancreatic and ovarian cancers.

22 Dec 2014

FDA approves Myriad’s BRACAnalysis CDx for use with ovarian cancer drug

Myriad Genetics, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for BRACAnalysis CDx to be used as the only companion diagnostic in conjunction with AstraZeneca’s drug Lynparza™ (olaparib).

22 Dec 2014

Study: Inactivating polymorphism may influence progression of ovarian and luminal breast cancer

A common polymorphism - a variation in a person's DNA sequence that is found with regularity in the general population - can lead to a chain of events that dictates how a tumor will progress in certain types of cancer, including a form of breast cancer as well as ovarian cancer, according to new research from The Wistar Institute that was published online by the journal Cancer Cell.

19 Dec 2014

New study identifies how SNAIL gene helps cancer cells break free from primary tumor

More than 90 percent of cancer-related deaths are caused by the spread of cancer cells from their primary tumor site to other areas of the body. A new study has identified how one important gene helps cancer cells break free from the primary tumor.

18 Dec 2014

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and GamaMabs Pharma, a company specialized in the development of monoclonal antibodies for cancer, today announce the extension of their partnership to develop the 3C23K antibody for the treatment of gynecological cancers.

16 Dec 2014

UC Davis researchers uncover complex relationship between p53 and Rbm38 proteins

Scientists have long known the p53 protein suppresses tumors. However, a recent animal study by UC Davis researchers has uncovered a complicated relationship between p53 and another protein, Rbm38, highlighting how the body calibrates protein levels. Too much Rbm38 reduces p53 levels, increasing the risk of cancer.

16 Dec 2014

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2).

15 Dec 2014

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

UNM professors create education pipeline to help students excel in STEM careers

Scientists discover hidden mechanism which could explain why some cancer therapies fail trials

MD Anderson and AstraZeneca to conduct multiple studies in ovarian, gynecologic cancers

UNC researchers discover how two genes interact to trigger worst form of ovarian cancer

BRCA1/2 analysis: an interview with Jurgi Camblong, CEO of Sophia Genetics

NCCS launches human clinical trial of new cancer vaccine

VolitionRx initiates pilot study to assess effectiveness of NuQ assays for ovarian cancer

Pfizer, Avon Foundation for Women reveal Avon-Pfizer Metastatic Breast Cancer Grants Program recipients

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Vermillion closes previously announced private placement with investors

Oncolytics Biotech submits Orphan Designation to EMA for treatment of ovarian, pancreatic cancers

FDA approves Myriad’s BRACAnalysis CDx for use with ovarian cancer drug

Study: Inactivating polymorphism may influence progression of ovarian and luminal breast cancer

New study identifies how SNAIL gene helps cancer cells break free from primary tumor

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

UC Davis researchers uncover complex relationship between p53 and Rbm38 proteins

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in